Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Danish diabetes-drug maker Novo Nordisk
With that in mind, let's take a closer look at Novo Nordisk's business and see what CAPS investors are saying about the stock right now.
Novo Nordisk facts
|Headquarters (Founded)||Bagsvaerd, Denmark (1925)|
|Market Cap||$76.27 billion|
|Trailing-12-Month Revenue||$10.15 billion|
CEO Lars Sorensen (since 2000)
CFO Jesper Brandgaard (since 2000)
|Return on Equity (Average, Past 3 Years)||31.5%|
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
Just last month, mitleg tapped Novo Nordisk as a rather healthy opportunity:
They are [an] all around great company. Good to work for. Clear leader in diabetes research. Surging sales. The growth rate is up there with your Apples and Salesforces of the world. It is a little pricey, but worth it for a market leader, and well-run company.
As the clear leader in diabetes-care products, Novo Nordisk stands in an ideal position to benefit from an unfortunately growing diabetic population. Over the next five years, Novo Nordisk is even expected to grow profits at a faster pace (18.5% per annum) than rivals Eli Lilly (-6.5%), Pfizer (3%), and Sanofi (-3.9%), as well as other drug giants like Merck
CAPS member KnockoutMouse lists several of Novo Nordisk's positives:
1. A clear leader in an industry with high barriers to competition.
2. Well managed and efficient: with a high ROIC and profit margin.
3. Strong balance sheet, free cash flow adequate to fund its dividend, and well managed debt.
4. A history of substantial dividends and dividend growth.
[Novo Nordisk] is the world leader in Diabetes care.
What do you think about Novo Nordisk, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Pfizer is a Motley Fool Inside Value pick. Salesforce.com is a Motley Fool Rule Breakers recommendation. Apple is a Motley Fool Stock Advisor selection. GlaxoSmithKline is a Motley Fool Global Gains pick. The Fool owns shares of and has written covered calls on GlaxoSmithKline. The Fool owns shares of Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.